Plain-English translation of NCT07546500 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase 3 trial testing a new medication called against standard chemotherapy for ovarian and related cancers that have become resistant to platinum drugs. The medication works by targeting cancer cells that have specific protein markers, pushing them toward cell death. The study will enroll 420 women to compare how well the new treatment works compared to chemotherapy that your doctor would normally choose.
Platinum-resistant ovarian cancers are difficult to treat, and patients need new options beyond standard chemotherapy. This medication targets a specific weakness in these cancer cells, which could offer better results with a daily pill instead of repeated chemotherapy infusions.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either take as a daily pill (5 days on, 2 days off each week) or receive your doctor's chosen chemotherapy regimen. Throughout the study, you'll have regular clinic visits to monitor how well the treatment is working through scans and blood tests, and to watch for side effects. The trial will track your cancer response and overall health to compare how the two treatments perform.
AI-generated summary from trial data · Aug 24, 2026 · Not medical advice
United States